Possible role of potassium channel, big K in etiology of Schizophrenia

Medical Hypotheses

Volumn 67, Issue 1, 2006, Pages 41-43

  Zhang, Lei ^a   Li, Xiaoxia ^a   Zhou, Rulun ^a   Xing, GuoQiang ^a  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; CALCIUM ACTIVATED POTASSIUM CHANNEL; CALMODULIN INHIBITOR; CHLORPROMAZINE; DIAZOXIDE; DOPAMINE; DOPAMINE 2 RECEPTOR; ESTROGEN; HALOPERIDOL; ION CHANNEL; NEUROLEPTIC AGENT; POTASSIUM CHANNEL; POTASSIUM CHANNEL STIMULATING AGENT; SEROTONIN;

ARTICLE; CLINICAL TRIAL; DRUG EFFECT; DRUG MECHANISM; HUMAN; MENTAL DISEASE; NERVE CELL EXCITABILITY; NEUROTRANSMISSION; POTASSIUM TRANSPORT; PRIORITY JOURNAL; SCHIZOPHRENIA; SYMPTOM;

ANIMALS; BRAIN; DIAZOXIDE; DOPAMINE; GAMMA-AMINOBUTYRIC ACID; HUMANS; LARGE-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS; MODELS, BIOLOGICAL; NEURONS; SCHIZOPHRENIA; SEROTONIN;

EID: 33646098928     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2005.09.055     Document Type: Article

References (16)

1. Delay J., Deniker P., and Harl J.M. The treatment of excitation and agitation states by a method of medication derived from hibernotherapy. Ann Method Psychol 110 (1952) 267
2. Carlsson A., and Lindqvist M. Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol Toxicol 20 (1963) 140-144
3. Potkin S.G., Alva G., Fleming K., Anand R., Keator D., Carreon D., et al. PET study of the pathophysiology of negative symptoms in Schizophrenia. Am J Psychiatry (2002) 227-237
4. Davis K.L., Kahn R.S., Ko G., and Davidson M. Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry 148 (1991) 1474-1486
5. Daly JM., Salloway S. Dopamine Receptors in the Human Brain 1994. Available from: www.PsychiatricTimes.
6. Shieh C.-C., Coghlan M., Sullivan J.P., and Gopalakrishnan M. Potassium Channels: Molecular Defects, Diseases, and Therapeutic Opportunities 52 4 (2000) 557-594
7. Centro de Estudios Cientificos, Valdivia, Chile. Differential effects of beta 1 and beta 2 subunits on BK channel activity. J Gen Physiol. 2005;125(4):395-411.
8. Lawson K. Is there a role for potassium channel openers in neuronal ion channel disorders?. Expert Opin Investig Drugs 9 10 (2000) 2269-2280
9. Shader R.I., and Greenblatt D.J. Potassium, antipsychotic agents, arrhythmias, and sudden death. J Clin Psychopharm 18 6 (1998) 427-428
10. Francis P.D. Effects of psychotropic medications on the pediatric electrocardiogram and recommendations for monitoring. Curr Opin Pediatr 14 2 (2002) 224-230
11. Dinan T.G. Calcium-activated potassium conductance. An alternative to the dopamine hypothesis of neuroleptic action?. Brit J Psychiat 151 (1997) 455-459
12. McCann J.D., and Welsh M.J. Neuroleptics antagonize a calcium-activated potassium channel in airway smooth muscle. J Gen Physiol 89 (1987) 339-352
13. Akhondzadeh S., Mojtahedzadeh V., Mirsepassi G.R., Moin M., Amini-Nooshabadi H., and Kamalipour A. Diazoxide in the treatment of schizophrenia: novel application of potassium channel openers in the treatment of schizophrenia. J Clin Pharm Ther 27 (2002) 453-459
14. Kay S.R., Fiszbein A., and Opler L.A. The positive and negative syndrome scale (PANSS) for Schizophrenia. Schizophr Bull 13 2 (1987) 261-276
15. Dick G.M., and Sanders K.M. (Xeno)estrogen sensitivity of smooth muscle BK channels conferred by the regulatory beta1 subunit: a study of beta1 knockout mice. J Biol Chem 276 (2001) 44835-44840
16. White R.E., Han G., Maunz M., Dimitropoulou C., El-Mowafy A.M., Barlow R.S., et al. Endothelium-independent effect of estrogen on Ca(2+)-activated K(+) channels in human coronary artery smooth muscle cells. Cardiovasc Res 53 (2002) 650-661